Last reviewed · How we verify
Sublingual Sufentanil
Sublingual sufentanil is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to produce rapid analgesia.
Sublingual sufentanil is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to produce rapid analgesia. Used for Acute pain management in opioid-tolerant patients, Breakthrough pain in opioid-tolerant patients.
At a glance
| Generic name | Sublingual Sufentanil |
|---|---|
| Also known as | Dsuvia Sublingual Product, Dsuvia, Sufenta |
| Sponsor | University of Minnesota |
| Drug class | Opioid agonist |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Sufentanil activates mu-opioid receptors, which modulate pain perception and emotional response to pain. The sublingual formulation allows rapid absorption through the oral mucosa, bypassing first-pass hepatic metabolism and enabling faster onset of action compared to oral opioids. This formulation is designed for acute pain management with quick onset kinetics.
Approved indications
- Acute pain management in opioid-tolerant patients
- Breakthrough pain in opioid-tolerant patients
Common side effects
- Respiratory depression
- Sedation
- Nausea
- Dizziness
- Constipation
- Hypotension
Key clinical trials
- Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil (PHASE1, PHASE2)
- DSUVIA Early Evaluation of Pain Trial (PHASE3)
- Management of Moderate to Severe Monotraumatic Pain With Sublingual Sufentanil in an Emergency Situation. (PHASE3)
- The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients (PHASE4)
- Assessing the Effects of Sublingual Sufentanil 30 µg on Postoperative Recovery (PHASE4)
- Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment (PHASE4)
- Medico-economic Evaluation of Sublingual PCA (Zalviso) Versus Oxycodone-PCA in the Management of Postoperative Pain. (NA)
- Safety and Efficacy of Patient Controlled Analgesia Using the Sublingual Sufentanil Tablet System (SSTS) in a Fast Track Rehabilitation Program After Total Knee Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sublingual Sufentanil CI brief — competitive landscape report
- Sublingual Sufentanil updates RSS · CI watch RSS
- University of Minnesota portfolio CI